Jefferies Group LLC reiterated their buy rating on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a research report released on Tuesday. The brokerage currently has a $21.00 price target on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2017 earnings at ($0.52) EPS, FY2018 earnings at ($0.33) EPS, FY2019 earnings at $1.39 EPS, FY2020 earnings at $1.31 EPS and FY2021 earnings at $1.73 EPS.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research report on Friday, May 26th. They set a buy rating and a $18.00 target price for the company. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, June 14th. BidaskClub cut shares of Vanda Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 11th. Piper Jaffray Companies set a $23.00 target price on shares of Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Vanda Pharmaceuticals presently has an average rating of Buy and an average price target of $21.25.

Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at 17.20 on Tuesday. The company’s 50-day moving average is $16.12 and its 200 day moving average is $14.96. The stock’s market cap is $771.56 million. Vanda Pharmaceuticals has a 52 week low of $12.70 and a 52 week high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 earnings per share. Analysts forecast that Vanda Pharmaceuticals will post ($0.47) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/vanda-pharmaceuticals-vnda-buy-rating-reiterated-at-jefferies-group-llc.html.

Large investors have recently modified their holdings of the company. Teachers Advisors LLC increased its stake in shares of Vanda Pharmaceuticals by 1.0% in the first quarter. Teachers Advisors LLC now owns 535,861 shares of the biopharmaceutical company’s stock worth $7,502,000 after buying an additional 5,180 shares during the period. FMR LLC increased its stake in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the period. Spark Investment Management LLC increased its stake in shares of Vanda Pharmaceuticals by 316.1% in the first quarter. Spark Investment Management LLC now owns 198,500 shares of the biopharmaceutical company’s stock worth $2,779,000 after buying an additional 150,800 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Finally, American International Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 1,491 shares during the period. Institutional investors and hedge funds own 86.49% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.